NCT07190833 2026-04-09A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)Bionoxx Inc.Phase 1 Recruiting27 enrolled